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Background: The evidence on the long-term economic effects of obesity is still scarce. This study aims to analyse
the impact of body mass index (BMI) and BMI-change on future pharmaceutical utilisation and expenditures.
Methods: Based on data from 2,946 participants in a German population-based health survey (MONICA/KORA,
1994/95) and the follow-up study (2004/05), drug intake and expenditures were estimated using a bottom-up
approach. Using univariate and multivariate methods, we analysed the impact of baseline BMI and BMI-change on
drug utilisation and expenditures after 10 years.
Results: The use of pharmaceuticals was more likely in moderately and severely obese compared to the normal
weight group (OR 1.8 and 4.0, respectively). In those who reported pharmaceutical intake, expenditures were about
40% higher for the obese groups. A 1-point BMI-gain in 10 years was, on average, associated with almost 6% higher
expenditures compared to a constant BMI.
Conclusion: The results suggest that obesity as well as BMI-gain are strong predictors of future drug utilisation
and associated expenditures in adults, and thus highlight the necessity of timely and effective intervention and
prevention programmes. This study complements the existing literature and provides important information on the
relevance of obesity as a health problem.
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The global prevalence of overweight and obesity has in-
creased significantly over recent decades. According to
the World Health Organization (WHO), 1.5 billion
adults were overweight in 2008. Of these, over 200 mil-
lion men and nearly 300 million women were obese [1].
The results of the German Telephone Health Survey
2003 show that, in Germany, about 70% of men and 50%
of women are overweight or obese. Compared with the
results of the German National Health Interview and
Examination Survey 1998, this implies a considerable in-
crease in adult prevalence rates [2].* Correspondence: christina.teuner@helmholtz-muenchen.de
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reproduction in any medium, provided the orObesity is a major public health concern, presenting a
huge burden of directly and indirectly obesity-related
diseases [3] as well as economic implications for society.
Besides lower skill attainment [4] and worse labour mar-
ket outcomes [5], these economic consequences also in-
clude higher health service expenditures – already
visible in childhood [6-8] and later on in adulthood [5].
The obesity-related drug prescription costs for Medicare
beneficiaries were analysed by Stuart et al. for the USA.
They concluded that overweight and obese people have
significantly higher drug expenditure compared with nor-
mal weight people, mainly owing to chronic diseases [9].
Two other US studies confirm these findings, reporting an
increase in average prescription drug expenditures by
80.4% compared with normal weight insurants [10] and
95% greater prescription drug expenditures for morbidly
obese compared with normal weight adults [11]. A further
cross-sectional study in the UK showed a considerable in-
crease in annual prescription drug expenditures with eachLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in men [12]. The German study by von Lengerke et al.
based on cross-sectional data also found higher expendi-
tures for prescription drugs for severely obese compared
with normal weight people [13].
However, most cost-of-illness or excess-cost studies
reporting drug expenditures focused on prescription
drugs, excluding patients’ out-of-pocket expenditures.
Furthermore, they are mostly based on cross-sectional
data and may therefore only draw conclusions regarding
short-term associations of BMI and expenditures. Yet,
obesity is also related to increased risk factors for several
diseases that might occur with a significant time lag
[14,15]. Information on the long-term influence of ele-
vated BMI on health care expenditures and the role of
weight development or maintenance is still scarce. The
studies by Højgaard and colleagues examined future
health care costs in relation to waist circumference and
BMI in a Danish prospective cohort study. Increased
waist circumference was associated with higher future
health care costs [16] even for constant levels of BMI
[17], but results were not reported separately for the in-
cluded cost components such as drug expenditures. Dilla
et al. found that medication costs for the treatment of
type 2 diabetes and related comorbidities were signifi-
cantly higher in Spanish type 2 diabetes patients who
gained BMI compared to those without a BMI increase
[18]. Based on self-reported height and weight, Thompson
et al. showed for a cohort of Kaiser Permanente members
aged 25–64 years that future healthcare costs were
higher for overweight, but especially for obese per-
sons. This association was specifically clear for phar-
macy costs, particularly diabetes and cardiovascular
medications [19].
Two German studies examined the subject of BMI and
BMI change and future healthcare costs based on differ-
ent surveys from the prospective MONICA/KORA co-
hort studies. One found higher future physician costs as
well as indirect costs owing to production losses for
obese participants compared with the normal weight
group [20]. The second study reports that those partici-
pants who maintained overweight, gained weight or lost
weight had higher outpatient physician costs compared
to participants who maintained normal weight over 7 to
10 years, especially after baseline obesity [21]. However,
to our knowledge, there are no publications analysing
the association of BMI/BMI change and costs for phar-
maceuticals for Germany so far.
To complement the existing literature, the present
study aims to analyse the impact of baseline BMI and
BMI change on future drug utilisation and expenditures
after 10 years in German adults based on the MONICA/
KORA surveys S3 and F3. This includes prescription
drug expenditures as well as out-of-pocket payments.Methods
Study population and sampling
The MONICA/KORA (Cooperative Health Research in
the Region of Augsburg) Survey S3 conducted from Oc-
tober 1994 to July 1995 is a population-based health sur-
vey. Participants were randomly selected from all
registered citizens of German nationality aged between
25 and 75 years in the region of Augsburg and its two
surrounding counties in southern Germany. The KORA
Follow-up study F3 was conducted in 2004/05, in which
all S3 participants who had not died, moved abroad or
to an unknown location or refused to be contacted were
contacted again. Both studies were approved by the re-
sponsible ethics committee (Bavarian Medical Associ-
ation, Munich).
In the S3 Survey, a sample of 4,856 participants was
examined (baseline response rate: 74.9%). Of these,
3,006 individuals (61.9%) also participated in the Follow-
up study F3 from October 2004 to May 2005: People
were considered ineligible for F3 if they had died in the
meantime (n = 405, 8%), lived too far outside the study
region or were completely lost to follow-up (n = 222,
5%) or had demanded deletion of their address data
(n = 270, 6%). Of the remaining 3,959 eligible people,
161 (4.1%) could not be contacted, 295 (7.5%) were un-
able to come because of illness or lack of time, and 497
(12.6%) were not willing to participate in this follow-up,
giving a response rate of 76%. For the following analyses,
all those with missing information on BMI in S3 or F3
and those with missing information on drug utilisation
in F3 were excluded (n = 44). Furthermore, individuals
with a BMI smaller than 18.5 kg/m2 were not included
(n = 16) because of the small sample size. Probable
underweight health conditions or even severe illness
might cause problems when including those participants
in the normal weight group. In sum, a complete dataset
including drug utilisation and BMI was available for
2,946 (61% of the S3/baseline sample) individuals in
both surveys.
Obesity
In both studies (Baseline S3 and Follow-up F3), body
weight and height of the participants were measured
anthropometrically in a standard medical examination
performed by trained medical staff. Calibration of meas-
uring instruments was censured by regular inspection
using standard weights. BMI was calculated for each par-
ticipant as weight in kilograms/(height in metres)2. Fol-
lowing the WHO definitions, the participants were
classified into four groups according to their BMI at
baseline: normal weight (18.5 ≤ BMI < 25); overweight
(25 ≤ BMI < 30); moderate obesity (obesity class 1: 30 ≤
BMI < 35); severe obesity (obesity class 2–3: BMI ≥ 35)
[22]. BMI change was defined as the absolute BMI
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pants who changed to the underweight group (BMI <
18.5) during the 10 years (n = 6 formerly normal weight
persons) were included in the normal weight group at
follow-up.
Sociodemographic and socioeconomic factors
In this analysis, gender, age and socioeconomic status in
the Follow-up study (F3) were used as potential con-
founders. Information on gender and age was available
for all participants. Determinants of socioeconomic sta-
tus (SES) were assessed in a structured face-to-face
health interview performed by trained medical staff [23].
SES was defined using the index compiled by Helmert
and colleagues, which is recommended for the German
population [24-26]. This index is based on scores for
educational level, occupational status and income in the
Follow-up study (F3). School education or vocational
training was used for the educational level. School edu-
cation was based on five categories (no school leaving
certificate, primary, secondary, tertiary school or general
qualification for university education), and seven cat-
egories were differentiated for vocational training ran-
ging from no vocational training to university degree.
Occupational status was grouped in a social class hier-
archy proposed by Helmert and Shea [24] for the German
labour market. For the equivalent household income, we
used the following groups: <50%, 50–69%, 70–89%,
90–109%, 110–129%, 130–149%, 150–169%, 170–189%
and >190% of the median income. Scores ranged from 1
to 9 (income, occupation) and 0 to 9 (education), respect-
ively, and were added up to build a global score for SES.
In the following analyses, participants were grouped into
five SES categories [24,27,28]: lower social class = scores
from 2 to 8; lower middle social class = scores from 9 to
11; middle social class = scores from 12 to 14; upper mid-
dle social class = scores from 15 to 18; and upper social
class = scores from 19 to 27. To prevent loss of data that
might cause systematic bias, missing values for SES (0.5%)
were imputed using the Markov chain Monte Carlo func-
tion method from the SAS procedure PROC MI based on
the variables educational level, occupational status and
income.
Measurement and assessment of drug utilisation and
expenditures
In the F3 Follow-up study, data on the participants’ utilisa-
tion of pharmaceuticals during the previous 7 days were
collected in a standardised computer-assisted personal
interview [29]. For the assessment of drug utilisation and
related expenditures, a rather narrow definition of phar-
maceuticals was applied with reference to §2 German
Pharmaceuticals Act (AMG), and ‘non-pharmaceuticals’
were excluded based on ATC (anatomic therapeuticchemical classification) groups. Specifically, vitamins and
dietary supplements (ATC A11/A12) were excluded as
well as ATC groups V02–V60 (varia), homoeopathic and
herbal medicines. Utilisation was defined as the number of
pharmaceuticals taken within the last 7 days.
Pharmaceutical expenditures were estimated based on
information on the name, pharmaceutical identification
number and dosage of drug intake. The pharmaceutical
identification number enables a well-defined attribution
of a pharmaceutical product including for example
name, package size, defined daily dose (DDD) and price.
First, the pharmaceutical identification number was used
to derive the package price. As suggested by costing
guidelines [30,31], the pharmaceuticals were priced using
2005 prices according to the national price list (available
by WidO – Scientific Institute of AOK). If a definite
identification of the pharmaceutical was impossible
owing to missing data and the information on the drug
name was imprecise (e.g. ‘pain killer’), the price of the
most frequently mentioned pharmaceutical in the par-
ticular ATC group was used for the largest freely dispos-
able package (N3) in a conservative approach. If only the
agent could be identified (e.g. ‘acetylsalicylic acid/ASA’),
the cheapest product in the particular ATC group was
assumed.
Drug expenditures per week were calculated as fol-
lows: if pharmaceuticals were taken regularly (84%), the
daily dose was multiplied by the number of days of drug
intake per week (both self-reported) and then divided by
the number of units per package. If pharmaceuticals
were not taken regularly, the information on daily dose
and days of intake were not given. In this case, we as-
sumed one intake per week in a conservative base ana-
lysis and used the DDD. In both cases, this gives the
proportion of the package that was used per week. This
proportion was then multiplied by the package price,
resulting in expenditures per week.
To test the sensitivity of utilisation and expenditure esti-
mates to changes in the underlying assumptions, univariate
sensitivity analyses were performed. First, to improve com-
parability with other studies, we also calculated the expen-
ditures for prescription-only drugs by BMI groups. Second,
in case the pharmaceuticals were not taken regularly, we as-
sumed daily intake instead of one intake per week to show
up the upper limit of estimated expenditures. Furthermore,
we assessed the impact of mandatory manufacturer and
pharmacy discounts for statutory health insurance on the
results: first, a 6% reduction in the manufacturer’s sell-
ing price (SGB V §130a) and, second, a reduction in the
pharmacy selling price of € 2 for prescription-only drugs
and 5% for other drugs (SGB V §130).
In order to improve comparability with other studies,
mean expenditures per week were also extrapolated to
1 year by multiplication by a factor of 52.
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In univariate analyses, the proportion of participants
with pharmaceutical intake, in total and separated by
ATC groups, was compared between BMI groups, and
chi-square tests were conducted to assess the signifi-
cance of differences. Analyses by ATC groups were
performed for those ATC groups that constitute more
than 5% of all pharmaceuticals in our sample (A:
Alimentary tract and metabolism; B: Blood and blood-
forming organs; C: Cardiovascular system; G: Genitouri-
nary system and sex hormones; H: Systemic hormonal
preparations, excluding sex hormones and insulins; M:
Musculoskeletal system; N: Nervous system; R: Respira-
tory system).
The proportion of prescription drugs was analysed
with regard to the four different BMI groups. Further-
more, the number of pharmaceuticals per person was
compared between BMI groups and tested for signifi-
cance using Kruskal–Wallis tests.
In order to account for non-normality of the cost data,
confidence intervals (CIs) were estimated for each BMI
group applying a non-parametric bootstrap approach
(1,000 replications) using a percentile method.
Expenditures were shown to have a skewed distribu-
tion: whereas some participants (32%) had zero expendi-
tures, there was a small number of people with high
drug expenditures, which is typically observed for health
care cost data [32,33]. To account for this skewness of
the data, two-part regression models were applied.
All regression analyses were adjusted for age, sex and
SES. Additionally, age was entered as a quadratic term
to account for a possible non-linear effect of age. ‘Nor-
mal weight’ was the reference group for the BMI classes
shown, ‘male’ for sex and ‘lower social class’ for SES.
A logistic regression model (GENMOD procedure in
SAS) for the binary response variable was calculated in the
first step of the two-part model predicting the odds ratio
of positive expenditures in the respective obesity class. In
the second step, positive expenditures were estimated
using a generalised linear model (GENMOD procedure in
SAS) assuming a gamma distribution with log-link func-
tion [34], which was supported by the modified Hosmer-
Lemeshow Test (p = 0.46) and the Pregibon Link Test
(p = 0.12). We report the exponents of regression esti-
mates that can be interpreted as factors. We also included
BMI as continuous non-linear effect in a generalised addi-
tive model, but this did not improve our model.
A separate two-part model was used to explore the re-
lationship between future drug expenditures in the years
2004/05 and the change in BMI between 1994/95 and
2004/05 while adjusting for baseline BMI. According to
the Akaike Information Criterion (AIC) the fit of this
model was slightly better compared to the model with-
out BMI change. The additional inclusion of interactionterms between baseline BMI group and BMI change was
tested, but did not show an improvement, nor did the
assumption of non-linearity of BMI change in a varying
coefficient model.
To improve the understanding of expenditure differ-
ences, the contribution of single ATC groups to total ex-
penditures was analysed and displayed by BMI group.
Mean expenditures were adjusted for age, sex and SES
using recycled predictions [35].
All statistical analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA: Version 9.2).
The statistical significance level was p < 0.05.
Results
Sample description
Table 1 shows the characteristics of the resulting study
population (n = 2,946) by BMI classes for the year 1994/
95. In total, 51% of the participants were female, with
significant differences between the four BMI groups.
The mean age was 57.6 years, increasing with higher
BMI groups. The SES status was higher among the nor-
mal weight participants compared with the overall sam-
ple. The proportion of lower SES classes is higher in
higher BMI groups. The average BMI gain decreases
with increasing baseline BMI, whereas standard devia-
tions increase.
Table 1 also shows the number of patients who stay in
the same obesity class from baseline to follow-up and
those who change from one category to another by
gaining or losing weight. Most participants remained in
the normal weight or overweight category after 10 years,
31% of the normal weight participants switched to the
overweight or obese classes, and 22% of the overweight
participants changed to a higher BMI group status. On
the other hand, over 20% of the severely obese and 15%
of the moderately obese participants managed to lose
weight.
Effect of obesity on future drug utilisation and
expenditures
Univariate analysis
In our sample, in total 6.309 drugs were reported. Table 2
displays the unadjusted results for the mean number of
pharmaceuticals and the associated expenditures by BMI
group. These univariate analyses show that both utilisa-
tion and expenditures increase significantly with increas-
ing BMI. The results of sensitivity analyses show that
mean expenditures are 12% lower if only prescription
drugs are regarded and 4% lower if pharmacy price dis-
counts are included. Assuming daily intake instead of
one intake per week for those participants who stated ir-
regular drug intake leads to an increase in expenditures
of 29%. However, the differences between BMI classes
are still significant.
Table 1 Sample description at the follow-up F3 by BMI classes of the Baseline KORA survey S3 (1994/95)
Baseline: S3 (1994/95)





n (%)b n (%)b n (%)b n (%)b n (%)b
F3 (2004/05) 2,946 100% 1,064 35.9% 1,327 44.8% 434 14.7% 121 4.1%
Sex Men 1,444 49.0% 368 34.6% 812 61.2% 224 51.6% 40 33.1% <.0001
Women 1,502 51.0% 696 65.4% 515 38.8% 210 48.4% 81 66.9%
Socio-economic status Lower class 463 15.7% 106 10.0% 218 16.4% 96 22.1% 43 35.5% <.0001
Lower middle class 601 20.4% 191 18.0% 258 19.4% 125 28.8% 27 22.3%
Middle class 627 21.3% 247 23.2% 286 21.6% 74 17.1% 20 16.5%
Upper middle class 728 24.7% 305 28.7% 306 23.1% 91 21.0% 26 21.5%
Upper class 527 17.9% 215 20.2% 259 19.5% 48 11.1% 5 4.1%
Normal weight or underweighta 854 29.0% 737 69.3% 115 8.7% 2 0.5% 0 0% <.0001
BMI group Overweight 1,298 44.1% 316 29.7% 918 69.2% 63 14.5% 1 0.8%
Moderate obesity 599 20.3% 11 1.0% 284 21.4% 280 64.5% 24 19.8%
Severe obesity 195 6.6% 0 0% 10 0.8% 89 20.5% 96 79.3%
Age (years) Mean (SD) 57.6 (12.8) 52.4 (12.1) 59.9 (12.4) 62.0 (12.0) 62.0 (11.2) <.0001
BMI change Mean (SD) 0.97 (2.1) 1.14 (1.77) 0.88 (2.04) 0.98 (2.57) 0.45 (3.21) 0.0008
Underweight: BMI < 18.5; normal weight: 18.5 ≤ BMI < 25; overweight: 25 ≤ BMI < 30; moderate obesity (obesity class 1): 30 ≤ BMI < 35; severe obesity (obesity class
2–3): BMI ≥ 35.
aPatients who changed to the underweight group during the 10 years (N = 6 formerly normal weight persons) were included in the normal weight group at
follow-up (F3).
bColumn percentages per gender/SES are shown.
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previous week. This percentage increases significantly with
increasing BMI. Detailed analyses for the most frequently
taken ATC groups show that this increase is significant for
the ATC groups A, C, H and M (see Table 3).Table 2 Drug utilisation and expenditures by baseline BMI gr
Total Normal we
n 2,946 1,064
Number of drugs Mean 2.14 1.42
SD 2.44 1.80
Costs/week (base) Mean 9.48 6.94
95% CIb [8.67-10.35] [5.63–8.5
Costs/week (prescription drugs)c Mean 8.35 5.67
95% CIb [7.60-9.11] [4.51–7.1
Costs/week (7/week)d Mean 12.25 9.67
95% CIb [11.34-13.20] [8.09–11.6
Costs/week (discounts)e Mean 9.08 6.60
95% CIb [8.30-9.93] [5.35–8.1
Costs per year (base) Mean 493 361
95% CIb [451–538] [293–446
ap-values were based on Kruskal–Wallis tests.
b Confidence intervals (CIs) were estimated based on 1,000 bootstrap replications.
cOnly prescription drugs.
dIn case the pharmaceuticals were not taken regularly, we assumed 7 days of intak
sensitivity analysis.
ePharmacy discounts, as regularised in the Social Security Code (SGB) V §130 and §Multivariate analysis
Table 4 displays the results of the two-step regression
models, where model 1 estimated the impact of baseline
BMI status on expenditures and model 2 shows the add-
itional effect of BMI change over the last 10 years. Inoup (unadjusted)
ight Overweight Moderate obesity Severe obesity p-valuea
1,327 434 121
2.23 3.09 4.12 <.0001
2.49 2.75 3.23
9.69 13.63 14.51 <.0001
7] [8.62–10.85] [10.99–16.76] [11.65–17.78]
8.58 12.80 13.55 <.0001
1] [7.67–9.63] [10.23–15.78] [10.84–16.56]
12.24 17.29 17.09 <.0001
4] [11.03–13.52] [14.36–20.71] [13.96–20.61]
9.31 13.13 13.93 <.0001
2] [8.29–10.43] [10.55–16.15] [11.26–16.92]
504 709 755 <.0001
] [448–564] [546–872] [607–925]
e instead of 1 (base analysis) to show up the upper limit of estimated costs as
130a, were incorporated as sensitivity analysis.
Table 3 Percentage of participants with drug intake by baseline BMI group








n = 2,946 n = 1,064 n = 1,327 n = 434 n = 121
Percentage 67.9% 60.3% 68.6% 78.8% 90.1% <.0001
Percentage by ATC group A: Alimentary tract and metabolism 16.3% 8.6% 17.3% 25.1% 42.1% <.0001
B: Blood and blood-forming organs 13.5% 7.9% 15.7% 18.7% 21.5% 0.3732
C: Cardiovascular system 36.9% 19.1% 40.5% 60.1% 70.2% <.0001
G: Genitourinary system and sex hormones 12.8% 16.7% 10.8% 9.2% 14.0% 0.2158
H: Systemic hormonal preparations, excl. sex
hormones + insulins
14.8% 12.9% 13.6% 19.8% 28.1% 0.0004
M: Musculoskeletal system 16.5% 11.6% 16.3% 27.0% 24.8% <.0001
N: Nervous system 16.4% 14.9% 16.2% 20.0% 19.0% 0.5355
R: Respiratory system 8.2% 7.7% 8.1% 9.4% 9.1% 0.4434
ap-values were adjusted for age, sex and SES.
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modelled in the first step and the amount of total drug
expenditures in the second step.
According to model 1, compared with the normal
weight group, the odds of pharmaceutical intake were
about 78% higher for moderately obese and more than
fourfold for severely obese participants (both significant).Table 4 Impact of baseline BMI and BMI change on drug expe
Model 1
Impact of baseline BMI only
1. Probability 2. Amount of cos
n = 2,946 n = 2,003
Parameter Odds ratio p-value Exp(est)a
Intercept 0.164 0.055 37.462
Age 0.974 0.449 0.951
Age squared 1.001 0.010 1.001
Sex: female 2.179 <.0001 0.967
SESb,d 0.347
Lower middle class 1.036 0.817 0.922
Middle middle class 0.984 0.913 0.894
Upper middle class 1.247 0.137 1.084
Upper class 1.108 0.514 1.079
BMIc,d <.0001
Overweight 1.188 0.087 1.132
Moderately obese 1.776 <.001 1.431
Severely obese 4.068 <.0001 1.361
BMI change – – –
Scale 2.718 – 1.839
AIC 3228 14385
aExponents of regression estimates are reported, that can be interpreted as factors.
Reference: bLower social class; cNormal weight.
dp-values for overall impact of group variable are given.Regarding the participants with pharmaceutical intake,
expenditures were about 40% higher for moderately and
severely obese participants. Regarding the possible con-
founders, age showed a significant U-shaped effect on
the amount of total expenditures. Women had signifi-
cantly higher odds of causing expenditures than men.
However, there were no significant differences betweennditures – two-step regression analysis
Model 2
Impact of baseline BMI and BMI change
ts if >0 1. Probability 2. Amount of costs if >0
n = 2,946 n = 2,003
p-value Odds ratio p-value Exp(est)a p-value
<.0001 0.168 0.058 33.191 <.0001
0.018 0.971 0.399 0.950 0.008
0.004 1.001 0.007 1.001 0.001
0.582 2.162 <.0001 0.960 0.462
0.112 0.324 0.045
0.389 1.034 0.830 0.929 0.387
0.256 0.987 0.930 0.914 0.314
0.400 1.253 0.129 1.095 0.292
0.476 1.120 0.472 1.123 0.233
0.001 <.0001 <0.0001
0.089 1.189 0.086 1.126 0.073
<.001 1.769 <.001 1.426 <.0001
0.025 4.134 <.0001 1.417 0.005
– 1.037 0.087 1.055 <.0001
– 2.718 – 2.099 –
3227 14322
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The overall impact of SES was not significant in this
model.
In an extended model, we tested the additional impact
of weight change over the last 10 years. The respective
results are also shown in Table 2 (model 2): BMI change
has no significant effect on the odds of drug intake (p =
0.087), but (for those with positive expenditures) does
have an effect on the amount of drug expenditures.
Thus, on average, a one-point BMI gain over the last
10 years is associated with 5.5% higher expenditures
compared with someone with a constant BMI, among
those that have positive expenditures. Compared with
model 1, however, additionally adjusting for BMI change
hardly affected the regression results for baseline BMI or
for the other variables. Only the overall effect of SES be-
comes significant in the second step of this extended
model.
Figure 1 shows the contributions of the six economic-
ally most important individual ATC groups to total ad-
justed expenditures for each BMI category. An increase
in mean drug expenditures is especially noticeable for
those pharmaceutical groups targeting the alimentary tract
and metabolism (differences to normal weight significant
for overweight (p = 0.002), moderate and severe obesity
(p < 0.0001)) and the cardiovascular system (differences to
normal weight significant for overweight, moderate and
severe obesity (p < 0.0001)). Also compared to the normal
weight group, expenditures for pharmaceuticals targeting
the respiratory system are significantly higher in the mod-
erately obese group (p = 0.006), but not for the severely
obese (p = 0.790). Also, the composition of drug expend-
iture by ATC groups differed significantly across BMI
groups. The ‘other’ group contains ATC groups for medi-
cines targeting blood and blood-forming organs (B),
dermatologicals (D), systemic hormonal preparations, ex-
cluding sex hormones and insulins (H), antiinfectives forFigure 1 Adjusted mean expenditures per week (€) by ATC group ansystemic use (J), antineoplastic and immunomodulating
agents (L), antiparasitic products, insecticides and repel-
lents (P) and sensory organs (S).
Discussion
The present study aims to analyse the impact of obesity
and change in BMI on future pharmaceutical utilisation
and expenditures based on data from two population-
based health surveys in Germany.
The percentage of participants with future drug intake
as well as the proportion of prescription drugs increases
significantly with rising baseline BMI group. Also, after
adjusting for age, sex and SES, moderately and severely
obese people have significantly higher odds of future drug
utilisation as well as higher future expenditures compared
with normal weight participants. This is consistent with
results from the existing international literature on the im-
pact of BMI on pharmaceutical expenditures based on
cross-sectional studies, e.g. [9-13]. BMI change has no sig-
nificant additional effect on the odds of drug intake, but
does have an effect on the amount of expenditures. On
average, a one-point BMI gain over the last 10 years is as-
sociated with 5.5% higher expenditures compared with
someone with a constant BMI. In total, 11% of the
formerly overweight or obese participants succeeded in
losing weight and changing to one of the lower BMI cat-
egories. Among those who have drug expenditures, on
average, a one-point BMI decrease during the last 10 years
was associated with 5% lower drug expenditures – inde-
pendent from baseline BMI. The independent effect of
weight change on costs is an important finding, which is
confirmed by an additional analysis adjusting for current
BMI instead of baseline BMI (in this case costs changed
by almost 3% per BMI point gained/lost). This shows that
successful prevention programmes, but also intervention
programmes for already obese people, have a strong po-
tential to reduce pharmaceutical costs in the long run.d baseline BMI group [95% CI]a.
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drug expenditures is especially noticeable for those
pharmaceutical groups targeting the alimentary tract
and metabolism (A) and the cardiovascular system (C).
In our sample, these groups particularly include drugs
for diabetes and coronary heart disease. This is in line
with the findings of an earlier study in the U.S [19] and
seems quite plausible, as obesity is a known risk factor
for diseases such as diabetes, dyslipidaemia, coronary
heart disease and cardiac insufficiency [14].
This is the first study analysing the longer term effects
of BMI and the effect of BMI change on pharmaceutical
utilisation and expenditures for Germany in a bottom-up
approach. This is possible because of the longitudinal de-
sign of the MONICA/KORA cohort study, which provides
patient-level information on drug intake (including out-of-
pocket expenditures), measured BMI and sociodemo-
graphic variables. Another advantage of this approach is
the possibility of comparing expenditures in population
subgroups, for example with respect to sociodemographic
variables and BMI. Although analyses based on compre-
hensive administrative statistics might give better esti-
mates of the actual level of expenditures for the respective
institution (e.g., health insurance), they mostly do not in-
clude patients’ out-of-pocket-expenditures. Furthermore,
these studies are often limited to cases of diagnosed obes-
ity rather than measured weight for height and do not
allow distinction between different degrees of obesity.
However, the study has some limitations. First, the
MONICA/KORA survey is not fully representative of
the population in Germany; for example, the two health
surveys are limited to people of German nationality [23],
and earlier studies have shown that obesity is more
prevalent in migrant cohorts [28]. Another reason for
the uncertainty of the results is drop-out. Regarding the
study sample for this analysis, a total of 1,877 people
dropped out from the Baseline survey S3 (1994/95) to
the Follow-up F3 (2004/05): of these, 19.6% were moder-
ately obese at baseline and 7.3% were severely obese.
Compared with the weight distribution in the analysed
sample, more severely and moderately obese people
dropped out than normal weight and overweight people.
Therefore, it cannot be excluded that people with a high
utilisation of health care services, for example owing to
greater age or illness, have dropped out before the Follow-
up KORA survey was conducted. Therefore, future
pharmaceutical expenditures due to obesity class (change)
may be underestimated in this analysis, particularly in the
case of moderately and severely obese participants.
Moreover, the statistically insignificant results of se-
verely obese participants and users might result from
low statistical power owing to the relatively small num-
ber of cases in this group compared with the other
weight categories.Although the problem of recall error should be small
considering the short time period, it cannot be excluded
as participants are asked to provide information retro-
spectively – in this case, to state the utilisation of phar-
maceuticals for the previous 7 days.
The estimation of drug expenditures was based on
several assumptions that may have caused under- or
overestimation. To reduce the uncertainty of drug util-
isation, sensitivity analyses were conducted. First, if
pharmaceuticals were not taken regularly, we assumed
one intake per week as a conservative base analysis. An
alternative assumption of daily intake leads to an in-
crease in mean expenditures of around 29%. Further-
more, sensitivity analysis was performed regarding legal
price discounts. Al-though all these univariate changes
affect the extent of expenditures in total, they barely af-
fected the differences between BMI classes. Discount
contracts between the pharmaceutical industry and
health care insurers, as introduced in 2003, could not be
taken into account as this information is not publicly
available.
In this study, we estimated the expenditures for drug
consumption based on utilisation during 1 week. The ac-
tual expenditures might be even higher if packages are
only partly used and leftovers are thrown away. More-
over, as utilisation of pharmaceuticals was requested for
the last 7 days, the extrapolated yearly expenditure esti-
mates should be interpreted with caution.
SES was included as a confounder in statistical ana-
lyses because it may influence health care utilisation as
an ‘enabling factor’ [36]. Yet, it has to be noted that SES
may also be associated with overweight and obesity, but
causality is not trivial [37,38]. Although low income
might have a negative impact on health behaviour
resulting in weight gain, overweight and obesity could
also impede labour market outcomes and cause lower
wages [5]. However, a recalculation of the regression
model without SES as a confounding variable did not
change our results.
Conclusions
The results of this analysis suggest that obesity is a
strong predictor of future drug utilisation and associated
expenditures in adults, and therefore highlight the ne-
cessity of timely and medically effective intervention and
prevention programmes. Moreover, BMI change is
shown to be an independent predictor of drug expendi-
tures. This may be an important finding regarding the
implementation and evaluation of obesity prevention
programmes: next to BMI reduction in overweight and
obese adults, the sustainable prevention of BMI gain
should be seen as an important goal and an indicator for
the success of an intervention. Based on these findings,
medically effective obesity prevention and intervention
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short- and long-term drug expenditures.
Yet, the relationship between BMI and health care ex-
penditures cannot be clearly defined as long as a com-
plex analysis including all causal relations between
obesity and chronic diseases is still lacking. Higher
health care utilisation might also be caused by a non-
observable disease. Owing to the complexity of obesity
as a health problem, the excess-cost approach was
chosen for this analysis, assuming that all excess utilisa-
tion is related to excess weight [39]. In order to com-
pletely understand the interaction between weight
status, weight development and the associated future
health care utilisation and costs from a lifetime perspec-
tive, further research is necessary. Besides longer-term
cohort- and modelling studies, this should also include
methodological research on cost assessment and meas-
urement as well as the economic evaluation of effective
obesity prevention programmes.
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